Cotización Murphy Canyon Acquisition - MURFU

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

16.36

Postura de Compra

14.46

Postura de Venta

17.84

Volume Operado de la Acción

0.00 Rango del Día 0.00

9.56 Rango de 52 semanas 19.91

Capitalización de Mercado [m]

245.4M

Precio Anterior

16.36

Precio de Apertura

Hora

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

Acciones en circulación

15,000,000

Rendimiento del Dividendo

Ratio Precio/Utilidad

-41.74

Beneficio por acción (BPA)

-0.4

turnover

Beneficio neto

-6.06M

Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company¿s licensed clinical assets are focused on idiopathic male infertility and autoimmun... Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company¿s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto¿s Thyroiditis. The Company¿s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto¿s Thyroiditis (HT) and Graves¿ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto¿s Thyroiditis and Graves¿ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI). Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.conduitpharma.com

Sede

Wilmington, Delaware, USA

Fundado

1970

Murphy Canyon Acquisition Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MURFU. The last closing price for Murphy Canyon Acquisition was US$16.36. Over the last year, Murphy Canyon Acquisition shares have traded in a share price range of US$ 9.56 to US$ 19.91.

Murphy Canyon Acquisition currently has 15,000,000 shares in issue. The market capitalisation of Murphy Canyon Acquisition is US$245.40 million. Murphy Canyon Acquisition has a price to earnings ratio (PE ratio) of -41.74.

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	5.53	51.0618651893	10.83	19.91	9.56	987	15.06841145	CS
156	6.32	62.9482071713	10.04	19.91	9.56	33777	10.10405665	CS
260	6.32	62.9482071713	10.04	19.91	9.56	33777	10.10405665	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
BBLGBone Biologics Corporation	US$ 3.55 (64.35%)	23.18M
RDHLRedhill Biopharma Ltd	US$ 0.549 (42.93%)	48.15M
IMRXImmuneering Corporation	US$ 1.49 (31.86%)	11.83M
CDNACareDx Inc	US$ 25.00 (25.06%)	33.22k
BIMIBIMI International Medical Inc	US$ 0.51 (21.43%)	2.4M
VWEVintage Wine Estates Inc	US$ 0.0315 (-39.31%)	6.54M
ALXOALX Oncology Holdings Inc	US$ 3.15 (-34.38%)	694.43k
NCNCnoco noco Inc	US$ 0.2145 (-25.26%)	2.37M
ATECAlphatec Holdings Inc	US$ 8.00 (-20.79%)	88.59k
NVANova Minerals Limited	US$ 4.18 (-18.20%)	19
HUGEFSD Pharma Inc	US$ 0.116 (14.85%)	50.08M
RDHLRedhill Biopharma Ltd	US$ 0.549 (42.93%)	48.15M
BBLGBone Biologics Corporation	US$ 3.55 (64.35%)	23.18M
RCMR1 RCM Inc	US$ 14.03 (8.93%)	15.82M
NVDANVIDIA Corporation	US$ 119.06 (1.74%)	15.75M